FAM
ARCT icon

Formidable Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Formidable Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90.3K Buy
11,700
+1,100
+10% +$8.67K 0.01% 380
2026
Q1 		$65K Buy
10,600
+500
+5% +$3.65K 0.01% 376
2025
Q4 		$186K Sell
10,100
-200
-2% -$2.16K 0.03% 388
2025
Q3 		$134K Sell
10,300
-4,400
-30% -$70.7K 0.02% 380
2025
Q2 		$156K Hold
14,700
– – 0.03% 372
2025
Q1 		$156K Sell
14,700
-3,500
-19% -$55.6K 0.03% 373
2024
Q4 		$309K Sell
18,200
-100
-0.5% -$1.88K 0.05% 296
2024
Q3 		$425K Sell
18,300
-500
-3% -$10.7K 0.07% 247
2024
Q2 		$458K Buy
18,800
+900
+5% +$27.3K 0.07% 245
2024
Q1 		$604K Buy
17,900
+2,350
+15% +$83.3K 0.1% 211
2023
Q4 		$490K Buy
15,550
+500
+3% +$11.9K 0.1% 173
2023
Q3 		$385K Buy
15,050
+100
+0.7% +$3.08K 0.09% 201
2023
Q2 		$429K Hold
14,950
– – 0.09% 185
2023
Q1 		$384K Sell
14,950
-900
-6% -$16.1K 0.08% 200
2022
Q4 		$269K Buy
15,850
+200
+1% +$3.49K 0.06% 241
2022
Q3 		$261K Buy
15,650
+700
+5% +$11.7K 0.06% 234
2022
Q2 		$235K Buy
14,950
+900
+6% +$17.7K 0.05% 254
2022
Q1 		$379K Buy
14,050
+1,100
+8% +$28.1K 0.07% 224
2021
Q4 		$498K Sell
12,950
-300
-2% -$12.2K 0.1% 188
2021
Q3 		$633K Buy
13,250
+925
+8% +$41.5K 0.12% 166
2021
Q2 		$346K Buy
12,325
+5,450
+79% +$184K 0.07% 207
2021
Q1 		$278K Buy
+6,875
New +$410K 0.06% 223
2020
Q3 		– Sell
-4,866
Closed -$263K – 267
2020
Q2 		$263K Buy
+4,866
New +$168K 0.08% 194
2017
Q4 		– Sell
-1,919
Closed -$14K – 117
2017
Q3 		$14K Buy
+1,919
New +$14.5K 0.01% 199
2017
Q1 		– Sell
-1,969
Closed -$29K – 204
2016
Q4 		$29K Sell
1,969
-329
-14% -$4.92K 0.01% 169
2016
Q3 		$40K Buy
2,298
+229
+11% +$7.4K 0.02% 166
2016
Q2 		$61K Buy
+2,069
New +$65.2K 0.03% 157

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Formidable Asset Management's ARCT Position: Q2 2026 in Review

Formidable Asset Management increased its Arcturus Therapeutics (ARCT) stake by 10% in Q2 2026, buying an estimated $8.67K and bringing the position to 11,700 shares worth $90.3K. The position accounts for 0.01% of the portfolio, ranked #380.

Formidable Asset Management first reported a position in ARCT in Q2 2016 and has held it in 27 quarters since. The position peaked at $633K in Q3 2021. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Formidable Asset Management held 11,700 shares of Arcturus Therapeutics worth $90.3K as of Q2 2026.
  • Formidable Asset Management bought 1,100 Arcturus Therapeutics shares in Q2 2026, an estimated $8.67K.
  • Arcturus Therapeutics made up 0.01% of Formidable Asset Management's portfolio in Q2 2026, its #380 holding.
  • Formidable Asset Management first reported a position in Arcturus Therapeutics in Q2 2016 and has held it in 27 quarters since.
  • Formidable Asset Management's Arcturus Therapeutics position peaked at $633K in Q3 2021.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Formidable Asset Management's 13F filing for Q2 2026, filed 17 Jul 2026.